PNP Therapeutics Names Claude Bennett and James Fuqua to Board of Directors
BIRMINGHAM, Ala. -- July 2, 2013
PNP Therapeutics, Inc.—an early-stage Birmingham-based biopharmaceutical
company created from research conducted at Southern Research Institute and The
University of Alabama at Birmingham (UAB)—today announced that Dr. J. Claude
Bennett and Mr. James F. Fuqua have joined its Board of Directors.
“We are honored to have these local leaders, with their very strong life
sciences management backgrounds, join the PNP Therapeutics Board of
Directors,” said John C. Lankford, Ph.D., president of Phase I Holdings, LLC
and chairman of the PNP Board. “Their expertise is especially beneficial and
timely now that PNP’s technology is in Phase 1 clinical trials for solid
In 1997, Dr. Bennett was designated by the University Board of Trustees as
Distinguished University Professor Emeritus. He served as President and Chief
Operating Officer of BioCryst Pharmaceuticals, Inc. from 1997-2009. Prior to
assuming this position, he served as President of the University of Alabama at
Birmingham (UAB). He joined the faculty of the UAB faculty in 1965, where he
served as Chairman of the Department of Microbiology, Director of the Division
of Clinical Immunology and Rheumatology, and Director of the Multipurpose
Dr. Bennett received his undergraduate degree from Samford University in
Birmingham in 1954 and his medical degree from Harvard Medical School in 1958.
He completed fellowships at the Massachusetts General Hospital, NIH, and the
California Institute of Technology. His work has appeared in more than 200
scholarly journals and publications, and he has served as President of the
American College of Rheumatology, President of the Association of American
Physicians, Chairman of the Health Sciences Policy Board of the Institute of
Medicine, and Editor of Cecil Textbook of Medicine.
Mr. Fuqua has demonstrated top level performance in multi-national and small
corporate strategies, business development, senior sales management and health
science organizations. He is currently Senior Consultant for The Center for
Leadership Studies/Performance Impact, Inc. Prior to that he was Vice
President, Strategic and Business Development for CE Outcomes, LLC and held
several senior management positions with Merck and Co. from 1979-2010. He
received a Bachelor of Science degree in Biology with minors in Chemistry and
Physics from Vanderbilt University in 1976.
ABOUT PNP THERAPEUTICS
PNP Therapeutics^®, Inc. is an early-stage, biopharmaceutical company engaged
in the development of a platform technology and proprietary products for the
treatment of cancer. The technology is currently in Phase 1 clinical trials.
PNP is the exclusive licensee of a comprehensive collection of patents that
broadly and specifically cover the Company's technology. These patents are
owned jointly by the University of Alabama at Birmingham (UAB) Research
Foundation and Southern Research Institute. Persons interested in learning
more about the PNP Therapeutics clinical trial can access the information at
www.ClinicalTrials.gov or contact Dr. Nancy Gray at firstname.lastname@example.org
or by phone at 205-581-2922.
For PNP Therapeutics
Rhonda Jung, 205-337-9634
Press spacebar to pause and continue. Press esc to stop.